<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report" dtd-version="1.1" specific-use="sps-1.7" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">ijcs</journal-id>
      <journal-title-group>
        <journal-title>International Journal of Cardiovascular Sciences</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Int. J. Cardiovasc. Sci.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2359-4802</issn>
      <issn pub-type="epub">2359-5647</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">xnxWMLkNYTxZk7ddgYQ5kcR</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S2359-56472018000300312</article-id>
      <article-id pub-id-type="doi">10.5935/2359-4802.20180016</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Reports</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Hypertrophic Cardiomyopathy, All Phenotypes in one</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Arias</surname>
            <given-names>An&#237;bal M</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Arenaza</surname>
            <given-names>Diego Perez de</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pizarro</surname>
            <given-names>Rodolfo</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Marenchino</surname>
            <given-names>Ricardo G</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Garagoli</surname>
            <given-names>Fernando</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
          <xref ref-type="corresp" rid="c1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rivello</surname>
            <given-names>Hern&#225;n Garcia</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Belziti</surname>
            <given-names>C&#233;sar</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <aff id="aff1">
          <institution content-type="orgname">Hospital Italiano de Buenos Aires</institution>
          <addr-line>
            <city>Buenos Aires</city>
          </addr-line>
          <country country="AR">Argentina</country>
          <institution content-type="original">Hospital Italiano de Buenos Aires, Buenos Aires - Argentina</institution>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="c1"><bold>Mailing Address: Fernando Garagoli.</bold> Peron, 4190. Postal Code: C1183AEG, Almagro, Ciudad Aut&#243;noma de Buenos Aires, Buenos Aires - Argentina. E-mail: <email>fernando.garagoli@hospitalitaliano.org.ar</email>
				</corresp>
        <fn fn-type="con">
          <p>
            <bold>Author contributions</bold>
          </p>
          <p>Conception and design of the research: Arias AM, Arenaza DP, Pizarro R, Marenchino RG, Garagoli F, Rivello HG, Belziti C. Acquisition of data: Arias AM, Arenaza DP, Pizarro R, Marenchino RG, Garagoli F, Rivello HG, Belziti C. Analysis and interpretation of the data: Arias AM, Arenaza DP, Pizarro R, Marenchino RG, Garagoli F, Rivello HG, Belziti C. Statistical analysis: Arias AM, Arenaza DP, Pizarro R, Marenchino RG, Garagoli F, Rivello HG, Belziti C. Writing of the manuscript: Arias AM, Arenaza DP, Pizarro R, Marenchino RG, Garagoli F, Rivello HG, Belziti C. Critical revision of the manuscript for intellectual content: Arias AM, Arenaza DP, Pizarro R, Marenchino RG, Garagoli F, Rivello HG, Belziti C.</p>
        </fn>
        <fn fn-type="conflict">
          <p>
            <bold>Potential Conflict of Interest</bold>
          </p>
          <p>No potential conflict of interest relevant to this article was reported.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>May-Jun</season>
        <year>2018</year>
      </pub-date>
      <volume>31</volume>
      <issue>3</issue>
      <fpage>312</fpage>
      <lpage>315</lpage>
      <history>
        <date date-type="received">
          <day>01</day>
          <month>03</month>
          <year>2017</year>
        </date>
        <date date-type="rev-recd">
          <day>06</day>
          <month>07</month>
          <year>2017</year>
        </date>
        <date date-type="accepted">
          <day>07</day>
          <month>07</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="en">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Cardiomyopathy, Hypertrophic</kwd>
        <kwd>Heart Failure</kwd>
        <kwd>Cardiomegaly</kwd>
        <kwd>Heart Transplantation</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Hypertrophic cardiomyopathy (HCM) is an intrinsic myocardial disorder characterized by cardiac hypertrophy (wall thickness &#8805; 15 mm), that is not explained by conditions of pressure overload (eg, hypertension, severe aortic stenosis).<xref ref-type="bibr" rid="B1">1</xref> HCM is the most common genetic primary cardiomyopathy, with a prevalence estimated to be about one in 500 adults in the general population.<xref ref-type="bibr" rid="B2">2</xref>
			</p>
      <p>More than 450 mutations have been identified in the 20 genes that cause different phenotypes. In most cases, HCM is associated with sarcomere protein gene mutations, and exhibits multiple phenotypic expressions. We present a case that combines all phenotypes.<xref ref-type="bibr" rid="B3">3</xref>
			</p>
    </sec>
    <sec sec-type="cases">
      <title>Case Report</title>
      <p>A 58-year-old hypertensive woman was admitted to the coronary care unit because of acute heart failure syndrome. The patient denied chest discomfort, illicit drug use or previous disease. The patient noted progressive dyspnea, abdominal swelling, edema of both legs and weight gain. Bilateral edema, ascites, jugular venous distention and (a 3-sound) gallop rhythm were evident on physical examination. The electrocardiogram (ECG) showed sinus rhythm, low QRS amplitude and a pseudoinfarction pattern (<xref ref-type="fig" rid="f1">Figure 1</xref>). The echocardiogram depicted global severe hipokinesis with preservation of lateral wall motion, and increased wall thickness with left chamber enlargement. Moderate pericardial effusion was also present. A continuous infusion of loop diuretics was administered.</p>
      <p>
        <fig id="f1">
          <label>Figure 1</label>
          <caption>
            <title>The electrocardiogram (ECG) showed sinus rhythm, low QRS amplitude and a pseudoinfarction pattern.</title>
          </caption>
          <graphic xlink:href="2359-5647-ijcs-31-03-0312-80016-gf01.jpg"/></fig>
      </p>
      <p>Thyroid hormones, iron tests and free light chain proteins were negative. Coronary angiography showed normal coronary arteries.</p>
      <p>Cardiac magnetic resonance revealed maximal wall thickness of 15 mm, left ventricular (LV) mass 262 g and LV mass index 178 g/m<sup>2</sup>, LV diastolic volume 194 mL, LV systolic volume 167 mL and ejection fraction 14%. A marked, diffuse transmural late gadolinium enhancement was also detected (<xref ref-type="fig" rid="f2">Figure 2. A</xref>-<xref ref-type="fig" rid="f2">F</xref>) (<xref ref-type="fig" rid="f2">Figure 2. A</xref>-<xref ref-type="fig" rid="f2">F</xref>)..</p>
      <p>
        <fig id="f2">
          <label>Figure 2</label>
          <caption>
            <title>Cardiovascular magnetic resonance shows increased left ventricular volume and wall thickness on cine images acquired in 4-chamber (A), long axis (2-chambers) (B) and medial short axis (C) views. Diffuse and transmural late gadolinium enhancement is showed (D, E, F) with preservation of basal segments. (G) Endomyocardial biopsy showed myocyte disarray.</title>
          </caption>
          <graphic xlink:href="2359-5647-ijcs-31-03-0312-80016-gf02.jpg"/></fig>
      </p>
      <p>With the picture of severe congestive heart failure in addition to an inverse relationship of ECG amplitude with wall thickness, an infiltrative cardiomyopathy was suspected. Right heart catheterization showed high filling pressures and low cardiac output, and endomyocardial biopsy showed diffuse fibrosis without specific changes. As the patient became refractory to optimal medical treatment, she underwent orthotopic heart transplantation. She recovered uneventfully and biopsy of the explanted heart was positive for HCM, showing severe interstitial fibrosis and extensive foci of myocyte disarray affecting the LV (<xref ref-type="fig" rid="f2">Figure 2.G</xref>).</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>HCM is a heterogeneous disease in terms of both genetics and phenotypes. For instance, it has been reported that distribution of hypertrophy in hypertrophic cardiomyopathy by troponin T gene differs no only among families but also within families.<xref ref-type="bibr" rid="B4">4</xref>
			</p>
      <p>The information available about the genotype - phenotype correlation in HCM is sparse.</p>
      <p>Sometimes HCM exhibits a "restrictive phenotype" characterized by restrictive filling and minimal or no left ventricular hypertrophy, which resembles idiopathic restrictive cardiomyopathy.<xref ref-type="bibr" rid="B5">5</xref>
			</p>
      <p>A smaller number of patients with HCM (5-10%) will progress to an end-stage form of the disease that is characterized by LV dilation, wall thinning and systolic dysfunction.<xref ref-type="bibr" rid="B6">6</xref> Despite the absence of systemic disease, the relationship between increased wall thickness, low ECG amplitude and severe diastolic dysfunction favors the diagnosis of a restrictive cardiomyopathy. Gadolinium enhancement was also typical for cardiac amyloidosis. In addition, there was no history of familial cardiac disease. Although endomyocardial biopsy even ruled out the diagnosis of cardiac amyloidosis, it also failed to confirm HCM, probably because the right ventricle was less affected.</p>
      <p>In this case, we reported increased left ventricular dimensions, depressed systolic function, ventricular hypertrophy and restrictive physiology, which are typical of a dilated, restrictive, hypertrophic phenotype. It is known that multiple genetic mutations can be present in the same person, which might explain the combination of three different features in this case.</p>
      <p>There is no similar case report in the literature.</p>
      <p>The limitation of this report is that we could not perform genetic testing as it is not currently available at our institution. In addition to the HCM diagnosis provided by biopsy it would have been of great value to know the specific gene mutation in order to puzzle out this "intriguing phenotype".</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="financial-disclosure">
        <p>
          <bold>Sources of Funding</bold>
        </p>
        <p>There were no external funding sources for this study.</p>
      </fn>
      <fn fn-type="other">
        <p>
          <bold>Study Association</bold>
        </p>
        <p>This study is not associated with any thesis or dissertation work.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>1 Task Force Members. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35(39): 2733-79. DOI: 10.1093/euheartj./Orgv-Ejehu284.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elliott</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Anastasakis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Borger</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Borggrefe</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cecchi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Charron</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)</article-title>
          <source>Eur Heart J</source>
          <year>2014</year>
          <volume>35</volume>
          <issue>39</issue>
          <fpage>2733</fpage>
          <lpage>2779</lpage>
          <pub-id pub-id-type="doi">10.1093/euheartj./Orgv-Ejehu284</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation>2 Lipshultz SE, Sleeper LA, Towbin JA, lowe AM, Cox GF, Lurie PR, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 2003;348(17):1647-55. DOI: 10.1056/NEJM.oa21715.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lipshultz</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Sleeper</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Towbin</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>lowe</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Lurie</surname>
              <given-names>PR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The incidence of pediatric cardiomyopathy in two regions of the United States</article-title>
          <source>N Engl J Med</source>
          <year>2003</year>
          <volume>348</volume>
          <issue>17</issue>
          <fpage>1647</fpage>
          <lpage>1655</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM.oa21715</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation>3 Ho CY, Charron P, Richard P, Garolami F, Van Spaendonck-Zwarts KY, Pinto Y. Genetic advances in sarcomeric cardiomyopathies: state of the art. Cardiovasc Res 2015; 105: 397-408. DOI: 10.1093/cv/cvv025.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ho</surname>
              <given-names>CY</given-names>
            </name>
            <name>
              <surname>Charron</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Richard</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Garolami</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Van Spaendonck-Zwarts</surname>
              <given-names>KY</given-names>
            </name>
            <name>
              <surname>Pinto</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Genetic advances in sarcomeric cardiomyopathies: state of the art</article-title>
          <source>Cardiovasc Res</source>
          <year>2015</year>
          <volume>105</volume>
          <fpage>397</fpage>
          <lpage>408</lpage>
          <pub-id pub-id-type="doi">10.1093/cv/cvv025</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation>4 Anan R, Shono H, Kisanuki A, Arima S, Nakao S, Tanaka H. et al. Patients with familial hypertrophiccardiomyopathy caused by a Phe110Ile missense mutation in the cardiactroponin T gene have variable cardiac morphologies and a favorableprognosis. Circulation.1998;98(5):391-7. PMID:9714088.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Shono</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kisanuki</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Arima</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nakao</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Patients with familial hypertrophiccardiomyopathy caused by a Phe110Ile missense mutation in the cardiactroponin T gene have variable cardiac morphologies and a favorableprognosis</article-title>
          <source>Circulation</source>
          <year>1998</year>
          <volume>98</volume>
          <issue>5</issue>
          <fpage>391</fpage>
          <lpage>397</lpage>
          <pub-id pub-id-type="pmid">9714088</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation>5 Kubo T, Gimeno JR, Bahl A, Steffenson U, Osman E, Thaman R, et al.Prevalence, Clinical Significance,and Genetic Basis of Hypertrophic Cardiomyopathy With Restrictive Phenotype. J Am Coll Cardiol 2007;49(25):2419-26. DOI: 10.1016/jack.2007.02061.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kubo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gimeno</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Bahl</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Steffenson</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Osman</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Thaman</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prevalence, Clinical Significance,and Genetic Basis of Hypertrophic Cardiomyopathy With Restrictive Phenotype</article-title>
          <source>J Am Coll Cardiol</source>
          <year>2007</year>
          <volume>49</volume>
          <issue>25</issue>
          <fpage>2419</fpage>
          <lpage>2426</lpage>
          <pub-id pub-id-type="doi">10.1016/jack.2007.02061</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation>6 Harris JK, Spirito P, Maron MS, zenovich AG, Formisano F, Lesser JR, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy.Circulation. 2006;114(3):216 -25. DOI: 10.1161./CIRCULATIONAHA.105.583.500.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harris</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Spirito</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Maron</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>zenovich</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Formisano</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lesser</surname>
              <given-names>JR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy</article-title>
          <source>Circulation</source>
          <year>2006</year>
          <volume>114</volume>
          <issue>3</issue>
          <fpage>216 </fpage>
          <lpage>2125</lpage>
          <pub-id pub-id-type="doi">10.1161./CIRCULATIONAHA.105.583.500</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="s1" xml:lang="pt">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relatos de Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Cardiomiopatia Hipertr&#243;fica, Todos os Fen&#243;tipos em um</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Arias</surname>
            <given-names>An&#237;bal M</given-names>
          </name>
          <xref ref-type="aff" rid="aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Arenaza</surname>
            <given-names>Diego Perez de</given-names>
          </name>
          <xref ref-type="aff" rid="aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pizarro</surname>
            <given-names>Rodolfo</given-names>
          </name>
          <xref ref-type="aff" rid="aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Marenchino</surname>
            <given-names>Ricardo G</given-names>
          </name>
          <xref ref-type="aff" rid="aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Garagoli</surname>
            <given-names>Fernando</given-names>
          </name>
          <xref ref-type="aff" rid="aff2"/>
          <xref ref-type="corresp" rid="c2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rivello</surname>
            <given-names>Hern&#225;n Garcia</given-names>
          </name>
          <xref ref-type="aff" rid="aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Belziti</surname>
            <given-names>C&#233;sar</given-names>
          </name>
          <xref ref-type="aff" rid="aff2"/>
        </contrib>
        <aff id="aff2">
          <institution content-type="original">Hospital Italiano de Buenos Aires, Buenos Aires - Argentina</institution>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="c2"><bold>Correspond&#234;ncia: Fernando Garagoli.</bold> Peron, 4190. CEP: C1183AEG, Almagro, Ciudad Aut&#243;noma de Buenos Aires, Buenos Aires - Argentina. E-mail: <email>fernando.garagoli@hospitalitaliano.org.ar</email>
				</corresp>
        <fn fn-type="con">
          <p>
            <bold>Contribui&#231;&#227;o dos autores</bold>
          </p>
          <p>Concep&#231;&#227;o e desenho da pesquisa: Arias AM, Arenaza DP, Pizarro R, Marenchino RG, Garagoli F, Rivello HG, Belziti C. Obten&#231;&#227;o de dados: Arias AM, Arenaza DP, Pizarro R, Marenchino RG, Garagoli F, Rivello HG, Belziti C. An&#225;lise e interpreta&#231;&#227;o dos dados: Arias AM, Arenaza DP, Pizarro R, Marenchino RG, Garagoli F, Rivello HG, Belziti C. An&#225;lise estat&#237;stica: Arias AM, Arenaza DP, Pizarro R, Marenchino RG, Garagoli F, Rivello HG, Belziti C. Reda&#231;&#227;o do manuscrito: Arias AM, Arenaza DP, Pizarro R, Marenchino RG, Garagoli F, Rivello HG, Belziti C. Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante: Arias AM, Arenaza DP, Pizarro R, Marenchino RG, Garagoli F, Rivello HG, Belziti C.</p>
        </fn>
        <fn fn-type="conflict">
          <p>
            <bold>Potencial Conflito de Interesse</bold>
          </p>
          <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
        </fn>
      </author-notes>
      <kwd-group xml:lang="pt">
        <title>Palavras-chave</title>
        <kwd>Cardiomiopatia Hipertr&#243;fica</kwd>
        <kwd>Insufici&#234;ncia Card&#237;aca</kwd>
        <kwd>Cardiomegalia</kwd>
        <kwd>Transplante de Cora&#231;&#227;o</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec sec-type="intro">
        <title>Introdu&#231;&#227;o</title>
        <p>A cardiomiopatia hipertr&#243;fica (CMH) &#233; uma doen&#231;a intr&#237;nseca do mioc&#225;rdio caracterizada por hipertrofia card&#237;aca (espessura da parede &#8805; 15 mm), n&#227;o causada por sobrecarga de press&#227;o (p.ex. hipertens&#227;o, estenose a&#243;rtica grave).<xref ref-type="bibr" rid="B1">1</xref> A CMH &#233; a cardiomiopatia prim&#225;ria gen&#233;tica mais comum, cuja preval&#234;ncia est&#225; estimada em aproximadamente 1 para cada 500 adultos na popula&#231;&#227;o geral.<xref ref-type="bibr" rid="B2">2</xref>
				</p>
        <p>Mais de 450 muta&#231;&#245;es foram identificadas em 20 genes respons&#225;veis por diferentes fen&#243;tipos. Na maioria dos casos, a CMH est&#225; associada com muta&#231;&#245;es nos genes que codificam prote&#237;nas do sarc&#244;mero e exibe muitas express&#245;es fenot&#237;picas. Apresentamos um caso que combina todos os fen&#243;tipos.<xref ref-type="bibr" rid="B3">3</xref>
				</p>
      </sec>
      <sec sec-type="cases">
        <title>Relato do Caso</title>
        <p>Uma mulher de 58 anos, hipertensa, foi admitida &#224; unidade coron&#225;ria por insufici&#234;ncia card&#237;aca aguda. A paciente negou desconforto no peito, uso de drogas il&#237;citas ou doen&#231;as pr&#233;vias. Percebeu dispneia progressiva, incha&#231;o do abd&#244;men e em ambas as pernas, al&#233;m de ganho de peso. No exame f&#237;sico, detectou-se edema bilateral, ascite, distens&#227;o da veia jugular, e ritmo de galope com 3 sons. O eletrocardiograma (ECG) mostrou ritmo sinusal, QRS com amplitude diminu&#237;da, e padr&#227;o de pseudo-infarto (<xref ref-type="fig" rid="f3">Figura 1</xref>). O ecocardograma mostrou hipocinesia grave, com movimenta&#231;&#227;o da parede lateral preservada, e aumento da espessura da parede e do ventr&#237;culo esquerdo (VE). Tamb&#233;m foi detectada efus&#227;o peric&#225;rdica moderada. Foi administrado diur&#233;tico de al&#231;a em infus&#227;o cont&#237;nua. Testes de horm&#244;nios tireoideanos, ferro e prote&#237;nas de cadeia livre leve deram negativos. A angiografia coron&#225;ria mostrou art&#233;rias coron&#225;rias normais.</p>
        <p>
          <fig id="f3">
            <label>Figura 1</label>
            <caption>
              <title>O eletrocardiograma apresentou ritmo sinusal, QRS com amplitude diminu&#237;da, e padr&#227;o de pseudo-infarto.</title>
            </caption>
            <graphic xlink:href="2359-5647-ijcs-31-03-0312-80016-gf01-pt.jpg"/></fig>
        </p>
        <p>A resson&#226;ncia magn&#233;tica card&#237;aca revelou espessura m&#225;xima da parede de 15 mm, massa ventricular esquerda de 262 g e &#237;ndice de massa do VE de 178 g/m<xref ref-type="bibr" rid="B2">2</xref>, volume diast&#243;lico do VE de 194 mL, volume sist&#243;lico do VE de 167mL e fra&#231;&#227;o de eje&#231;&#227;o de 14%. Tamb&#233;m foi marcante a presen&#231;a de realce tardio transmural difuso com gadolinium (<xref ref-type="fig" rid="f4">Figura 2A</xref>-<xref ref-type="fig" rid="f4">F</xref>) (<xref ref-type="fig" rid="f4">Figura 2 A</xref>-<xref ref-type="fig" rid="f4">F</xref>)..</p>
        <p>
          <fig id="f4">
            <label>Figura 2</label>
            <caption>
              <title>A resson&#226;ncia magn&#233;tica (RM) cardiovascular apresenta aumento do volume do ventr&#237;culo esquerdo e da espessura da parede em imagens de cine-RM adquiridas nos planos de 4 c&#226;maras (A), eixo longo (2 c&#226;maras), (C) e eixo curto medial. O realce tardio difuso e transmural com gadolinium &#233; apresentado em D, E, e F, com segmentos basais preservados. (G) A bi&#243;psia endomioc&#225;rdica apresentou desorganiza&#231;&#227;o dos mi&#243;citos.</title>
            </caption>
            <graphic xlink:href="2359-5647-ijcs-31-03-0312-80016-gf02-pt.jpg"/></fig>
        </p>
        <p>Diante do quadro de insufici&#234;ncia card&#237;aca congestiva e da rela&#231;&#227;o inversa da amplitude do ECG com a espessura da parede, suspeitou-se de cardiomiopatia restritiva (infiltrativa). O cateterismo card&#237;aco esquerdo mostrou press&#227;o de enchimento aumentado e baixo d&#233;bito card&#237;aco, e a bi&#243;psia endomioc&#225;rdica revelou fibrose difusa, sem altera&#231;&#245;es espec&#237;ficas. Como a paciente tornou-se resistente ao tratamento m&#233;dico, foi submetida ao transplante card&#237;aco ortot&#243;pico. A paciente recuperou-se sem intercorr&#234;ncias e a bi&#243;psia do cora&#231;&#227;o explantado foi positiva para CMH, com fibrose intersticial grave e focos extensos de desorganiza&#231;&#227;o dos mi&#243;citos, acometendo o VE (<xref ref-type="fig" rid="f4">Figura 2.G</xref>).</p>
      </sec>
      <sec sec-type="discussion">
        <title>Discuss&#227;o</title>
        <p>A CMH &#233; uma doen&#231;a heterog&#234;nea em termos gen&#233;ticos e fenot&#237;picos. Por exemplo, a distribui&#231;&#227;o da hipertrofia pelo gene da troponina T na cardiomiopatia hipertr&#243;fica difere-se n&#227;o s&#243; entre fam&#237;lias como tamb&#233;m dentro de uma mesma fam&#237;lia.<xref ref-type="bibr" rid="B4">4</xref>
				</p>
        <p>Informa&#231;&#245;es acerca da correla&#231;&#227;o genot&#237;pica-fenot&#237;pica s&#227;o escassas. &#192;s vezes, a CMH apresenta um fen&#243;tipo "restritivo", caracterizado por enchimento restritivo e hipertrofia do VE m&#237;nima ou ausente, semelhante &#224; cardiomiopatia restritiva idiop&#225;tica.<xref ref-type="bibr" rid="B5">5</xref>
				</p>
        <p>Um menor n&#250;mero de pacientes com CMH (5-10%) evoluir&#225; para o est&#225;gio terminal da doen&#231;a, que &#233; caracterizado por dilata&#231;&#227;o do VE, redu&#231;&#227;o na espessura da parede, e disfun&#231;&#227;o sist&#243;lica.<xref ref-type="bibr" rid="B6">6</xref>
				</p>
        <p>Apesar da aus&#234;ncia de doen&#231;a sist&#234;mica, a presen&#231;a de espessura da parede aumentada, baixa amplitude no ECG e disfun&#231;&#227;o diast&#243;lica grave &#233; sugestiva de cardiomiopatia restritiva. O realce com gadolinium tamb&#233;m foi caracter&#237;stico de amiloidose card&#237;aca. Al&#233;m disso, n&#227;o havia hist&#243;ria de doen&#231;a card&#237;aca familiar. Apesar de a bi&#243;psia endomioc&#225;rdica haver descartado o diagn&#243;stico de amiloidose card&#237;aca, tamb&#233;m n&#227;o confirmou o de CMH, provavelmente pelo fato de o ventr&#237;culo direito ter sido pouco afetado.</p>
        <p>No presente caso, encontramos dimens&#245;es aumentadas do VE, fun&#231;&#227;o sist&#243;lica diminu&#237;da, hipertrofia ventricular e fisiologia restritiva, que caracterizam um fen&#243;tipo dilatado, restritivo, hipertr&#243;fico.</p>
        <p>Sabe-se que muitas muta&#231;&#245;es gen&#233;ticas podem estar presentes em um mesmo indiv&#237;duo, o que pode explicar a combina&#231;&#227;o de tr&#234;s caracter&#237;sticas diferentes no presente caso.</p>
        <p>N&#227;o existe relato de caso similar na literatura.</p>
        <p>A limita&#231;&#227;o deste estudo deve-se a n&#227;o realiza&#231;&#227;o de um teste gen&#233;tico, uma vez que esse ainda n&#227;o est&#225; dispon&#237;vel em nossa institui&#231;&#227;o. Al&#233;m do diagn&#243;stico de CMH obtida por bi&#243;psia, seria de grande valor conhecer a muta&#231;&#227;o gen&#233;tica espec&#237;fica a fim de se esclarecer tal fen&#243;tipo "intrigante".</p>
      </sec>
    </body>
    <back>
      <fn-group>
        <fn fn-type="financial-disclosure">
          <p>
            <bold>Fontes de Financiamento</bold>
          </p>
          <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
        </fn>
        <fn fn-type="other">
          <p>
            <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
          </p>
          <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
